BridgeMD
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Participants with Previously Untreated Extensive Stage Small Cell Lung Cancer
EU CTIS ID: 2024-517490-24-00
What this study is testing
- To evaluate the safety and tolerability of ABBV-706 in combination with atezolizumab - To optimize and select the recommended Phase 3 dose (RP3D) of ABBV-706 in combination with atezolizumab - To evaluate efficacy as measured by progression-free survival (PFS) of ABBV-706 in combination with atezolizumab
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 during the screening period prior to the first dose of study treatment.
- Participants must be considered suitable to receive a platinum-based chemotherapy or atezolizumab regimen as first line treatment for ES-SCLC. Chemotherapy must contain carboplatin in combination with etoposide.
- Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
You likely can't join if
- Histologically or cytologically confirmed mixed small cell lung cancer (SCLC).
- Prior treatment of any kind for LS-SCLC.
- Prior systemic therapy for the treatment of first line ES-SCLC.
- Participants with known active/symptomatic central nervous system (CNS) metastases
- Participants with a history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest CT scan
The study team makes the final eligibility decision.
Where it's taking place
- Serbia
- Japan
- Turkey
- Israel
- Canada
- Korea, Republic of
- China
- Taiwan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Serbia; Japan; Turkey; Israel; Canada; Korea, Republic of and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.